Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States
These findings highlight the significant uncompensated burden placed on oncology practices, raising concerns about how non-reimbursed tasks may affect patient care, staff retention, and the financial sustainability of these practices.
Authors
- Kejal Jadhav
- Jason T. Shafrin (ORCID: https://orcid.org/0000-0001-8444-5979)
- Nadine Zawadzki (ORCID: https://orcid.org/0000-0002-3379-9424)
- Andrea Damon
- Katharine Batt (ORCID: https://orcid.org/0000-0003-3672-8741)
- David Wei (ORCID: https://orcid.org/0000-0002-0000-4533)
- Daisy Yang
- Kathryn Spurrier
- Sabiha Quddus
- Cheryl Warren
Institutions
- Novartis (Switzerland) (CH)
- Sprout Design (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1080/13696998.2025.2593796
- Citations
- 1
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.13